Tumor related mortality and Tumor recurrence in endometrial cancer: Analysis in 276 patients

What is it about?

In this manuscript, we assessed tumor recurrence and tumorrelated mortality in a clinical series of endometrial cancer patients. A retrospective evaluation of 276 patients (mean age 64 years) with histologically confirmed endometrial cancer treated at a single hospital in Madrid (Spain) was conducted. The median followup was estimated using the inverse Kaplan–Meier method. Salient findings were endometrioid carcinoma (84.8% of cases), grade G1 (48.9%) and stages IB (35.1%) and IC (23.2%). Myometrial infiltration >50% was documented in 31.2% of cases and lymphovascular space invasion in 11.9%. After surgery, 52.5% of patients were classified into the low risk group, 21.4% into the intermediate risk group and 26.1% into the high risk group. Tumor recurrence occurred in 14.5% of patients, with an estimated median followup of 45 months (95% confidence interval (CI): 41.2–48.8), locoregional recurrence in 42.5% and distant recurrences in 57.5%. Furthermore, 40% of tumor recurrences developed during the first year after primary treatment and 90% over the first 3 years of followup. The tumorrelated mortality rate was 15.9%. The estimated median followup was 46 months (95% CI: 43.0–49.0). Furthermore, 5.07% of death because of tumor developed during the first year after primary treatment and 13.77% over the first 3 years of followup. The rates of tumorrelated death and tumor recurrence in endometrial cancer patients are low, with the highest percentages occurring within 3 years of primary treatment. Most of the recurrences occur outside the pelvis.

Featured Image

Why is it important?

In summary, the rates of tumorrelated death and tumor recurrence in endometrial cancer patients are low, with the highest percentages occurring within 3 years of primary treatment. Recurrences are often found outside the pelvis because of the higher therapeutic effort concentrated on this focus. It is probable that systemic chemotherapy in endometrial cancer patients with high risk of recurrence may help to reduce the percentage of distant metastasis.

Perspectives